The new Luliconazole and Clobetasol Propionate combination was approved for the treatment of a variety of skin diseases. The goal of this research is to create and validate a rapid, steady, precise, and cost-effective derivative spectrophotometry procedure for analysing the recently approved Luliconazole and Clobetasol Propionate combination.
Methodology: The absorbance of LLZ and CLP was measured at 312nm (ZCP of CLP) and 249nm (ZCP of LLZ) in this first derivative spectroscopic approach. The concentrations used to establish linearity ranged from 10-50 g/ml for Luliconazole and 5-25 g/ml for Clobetasole Propionate.
As a result of the strategy described above, the R2 values for LLZ and CLP are 0.9988 and 0.9961, respectively. Recovery studies were used to statistically validate the accuracy and reproducibility of the intended method. Luliconazole and Clobetasol Propionate were shown to have 99.45 percent and 99.43 percent percent recovery, respectively. The limit of detection for LLZ is 0.0054 g/ml and the limit of quantification is 0.0164 g/ml, while the limit of detection for CLP is 0.0009 g/ml and the limit of quantification is 0.0027 g/ml.
Conclusion: Based on the research, a method was developed that demonstrates a fast, precise, exact, and conveniently accessible laboratory procedure for evaluating combination medications on a regular basis.
Nootan Pharmacy College, Sankalchand Patel University, Visnagar, India and Laxminarayandev College of Pharmacy, Bharuch, India.
Laxminarayandev College of Pharmacy, Bharuch, India and Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, India.